Syndax Pharmaceuticals Inc
SNDX
14 insider filings · Latest: Jun 11, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Jul 16, 2025 | Jul 16 7:21 PM | Metzger Michael A | Proposed Sale | 7,534 | $9.29 | $70.0K | — | View → |
| Jul 10, 2025 | Jul 10 7:42 PM | Gallagher Neil | Proposed Sale | 9,679 | $9.26 | $89.7K | — | View → |
| Mar 4, 2025 | Mar 4 10:10 PM | MICHAEL METZGER | Proposed Sale | 13,888 | $15.48 | $215.0K | — | View → |
| Feb 10, 2025 | Feb 10 8:29 PM | Goldan Keith A. | Proposed Sale | 3,777 | $15.50 | $58.6K | — | View → |
| Feb 10, 2025 | Feb 10 8:20 PM | Metzger Michael A | Proposed Sale | 13,288 | $15.50 | $206.0K | — | View → |
| Feb 10, 2025 | Feb 10 8:17 PM | Gallagher Neil | Proposed Sale | 4,618 | $15.50 | $71.6K | — | View → |
← Previous
Page 2 of 2
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Jun 12 9:09 PM | Nicholas A.J. BotwoodHead of R&D, CMO | Option Exercise | 31,235 | $13.82 | 0(D) | View → |
| Jun 11, 2026 | Jun 12 9:09 PM | Nicholas A.J. BotwoodHead of R&D, CMO | Option Exercise | 22,515 | $13.82 | 0(D) | View → |
| Feb 4, 2026 | Feb 6 10:54 PM | Michael A MetzgerDirector, Chief Executive Officer | Grant/Award | 440,000 | $20.43 | 440,000(D) | View → |
| Feb 4, 2026 | Feb 6 10:53 PM | Keith A. GoldanChief Financial Officer | Grant/Award | 118,000 | $20.43 | 118,000(D) | View → |
| Feb 4, 2026 | Feb 6 9:50 PM | Nicholas A.J. BotwoodHead of R&D, CMO | Grant/Award | 144,700 | $20.43 | 144,700(D) | View → |